Kintara Therapeutics Current Valuation vs. Current Ratio
| KTRADelisted Stock | USD 6.30 0.14 2.17% |
For Kintara Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kintara Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kintara Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kintara Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kintara Therapeutics over time as well as its relative position and ranking within its peers.
Kintara |
Kintara Therapeutics Current Ratio vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Kintara Therapeutics's current stock value. Our valuation model uses many indicators to compare Kintara Therapeutics value to that of its competitors to determine the firm's financial worth. Kintara Therapeutics is rated below average in current valuation category among its peers. It is rated below average in current ratio category among its peers . The ratio of Current Valuation to Current Ratio for Kintara Therapeutics is about 5,415,045 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kintara Therapeutics' earnings, one of the primary drivers of an investment's value.Kintara Current Valuation vs. Competition
Kintara Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is now estimated at about 2.91 Billion. Kintara Therapeutics maintains roughly 17.98 Million in current valuation contributing less than 1% to equities under Health Care industry.
Kintara Current Ratio vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Kintara Therapeutics |
| = | 17.98 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Kintara Therapeutics |
| = | 3.32 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Kintara Current Ratio Comparison
Kintara Therapeutics is currently under evaluation in current ratio category among its peers.
Kintara Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Kintara Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kintara Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Kintara Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Kintara Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. Kintara Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Kintara Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Kintara Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kintara Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kintara Therapeutics' important profitability drivers and their relationship over time.
Use Kintara Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kintara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kintara Therapeutics will appreciate offsetting losses from the drop in the long position's value.Kintara Therapeutics Pair Trading
Kintara Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Kintara Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kintara Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kintara Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kintara Therapeutics to buy it.
The correlation of Kintara Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kintara Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kintara Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kintara Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Kintara Therapeutics position
In addition to having Kintara Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Blockchain Thematic Idea Now
Blockchain
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |